Octaplaslg (Human Plasma Protein)

Human Plasma Protein, the active ingredient in Octaplaslg, is a plasma‑derived protein therapy presented as a sterile liquid for intravenous use. It is used to support hemostasis in patients with complex coagulation needs, such as those undergoing major surgery or experiencing massive hemorrhage. GNH USA supplies Octaplaslg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

GNH USA supplies Octaplaslg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

Octaplaslg is a plasma‑derived protein therapy that addresses disorders of the coagulation cascade and related bleeding complications. - Major surgery: provides comprehensive coagulation factor replacement to reduce intra‑operative bleeding. - Trauma and massive hemorrhage: restores deficient clotting factors to help achieve hemostasis. - Liver disease‑related coagulopathy: supplies functional plasma proteins to improve clotting capacity. - Cardiac surgery with cardiopulmonary bypass: supports hemostasis during and after bypass. - Obstetric hemorrhage: aids in controlling bleeding when conventional blood components are insufficient.

Adverse reactions to Octaplaslg are generally related to its plasma origin and the infusion process.

Common Side Effects: - Fever: mild temperature elevation occurring shortly after infusion. - Chills: transient shaking or feeling cold during or after administration. - Headache: mild to moderate headache reported by some recipients. - Nausea: occasional feeling of queasiness post‑infusion. - Hypotension: slight drop in blood pressure during the infusion. - Allergic rash: localized skin redness or urticaria.

Serious or Rare Side Effects: - Anaphylaxis: severe, life‑threatening allergic reaction requiring immediate medical intervention. - Transfusion‑related acute lung injury (TRALI): acute respiratory distress following infusion. - Hemolytic transfusion reaction: destruction of red blood cells due to incompatibility. - Viral transmission: risk of infection despite donor screening and viral inactivation. - Thromboembolic events: formation of clots in vessels leading to stroke or pulmonary embolism.

When using Octaplaslg, clinicians should assess patient history and monitor for reactions throughout the infusion. - Verify compatibility: confirm ABO and Rh compatibility before administration. - Monitor vital signs: observe blood pressure, temperature, and respiratory status during infusion. - Assess for prior reactions: review any history of plasma product intolerance or allergic responses. - Use aseptic technique: maintain sterility to prevent contamination. - Adjust volume: consider patient fluid status to avoid overload. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze, and use within the recommended period after thawing.

Octaplaslg may interact with other blood products or medications that affect coagulation, requiring careful clinical oversight.

Major Interactions (Avoid): - Anticoagulants (e.g., heparin, warfarin): concurrent use can blunt the hemostatic benefit and increase bleeding risk. - High‑dose fibrinolytics: may counteract clot‑forming activity and precipitate uncontrolled bleeding.

Moderate Interactions (Monitor Closely): - Aspirin and other antiplatelet agents: may require dose adjustment or timing changes. - Immunoglobulin therapy: monitor for additive infusion‑related reactions. - Certain antibiotics (e.g., vancomycin): observe for enhanced risk of hypersensitivity. - Diuretics: watch for fluid balance shifts when large volumes are infused.